The Two Stocks You Should Never Give Up On, No Matter What

I've watched Apple and Eli Lilly take a beating this year, and honestly? I'm thrilled. Nothing makes me happier than seeing quality stocks on discount, especially when Wall Street's short-term panic creates buying opportunities for the rest of us.

Apple's been dragged through the mud over tariff concerns, yet they're still crushing it financially. Their Q3 revenue jumped 10% to $94 billion! Meanwhile, everyone's obsessing over their AI "failures" while completely missing what really matters: their service revenue hit $27.4 billion, up 13.3% year-over-year. This high-margin cash cow now represents almost 30% of their business.

Look, I've owned Apple for years, and the idiots dumping shares because of some tariff headlines are the same ones who'll be buying back at much higher prices. Their device ecosystem is a fortress with over 2.35 billion active devices - a captive audience that keeps growing. And that pathetic-looking 0.4% dividend? They've doubled it in ten years. Do the math.

As for Eli Lilly, the stock tanked because their weight loss drug "only" achieved 12.4% weight reduction instead of the ridiculous expectations Wall Street had conjured. Give me a break! Their GLP-1 drugs Mounjaro and Zepbound are projected to hit $62 billion in sales by 2030. That's not just impressive; it's historic.

The shortsighted market misses the bigger picture - Lilly's diversified across immunology, oncology, and neurology. While everyone obsesses over weight loss drugs, Lilly's quietly building an innovation powerhouse with a dividend that's grown 200% in a decade.

I'm not saying these stocks will explode tomorrow. But ten years from now? You'll kick yourself for not buying when everyone else was panicking. These aren't trendy tech startups - they're businesses with proven ability to adapt, innovate, and dominate their industries.

When the market gives you quality at a discount, you don't hesitate. You buy.